Femasys stock.

Femasys Inc () Stock Market info Recommendations: Buy or sell Femasys stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Femasys share forecasts, stock quote and buy / sell signals below.According to present data Femasys's FEMY shares and potentially its market environment have been in bearish …Femasys has a market capitalisation of US$22m and burnt through US$11m last year, which is 50% of the company's market value. ... It does not constitute a recommendation to buy or sell any stock ...Sep 29, 2023 · Femasys Inc. (NASDAQ: FEMY) shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13. Find the latest Earnings Report Date for Femasys Inc. Common Stock (FEMY) at Nasdaq.com.

In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.Shares Outstanding 21.65 M Public Float 19.48 M Yield FEMY is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short Interest (10/31/23) …Web

Portfolio Overview. Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs. Femasys has an expansive, internally-created intellectual property ...

Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference. 08/31/2023. Femasys Inc. Obtains Medical Device Establishment License from Health Canada. 08/10/2023. Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update. 08/03/2023.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …The Femasys Inc (NASDAQ: FEMY) stock price continued rallying higher on Monday following Friday’s 96% rally as investor sentiment towards the company remained decidedly bullish. The persistent demand for FEMY shares can be seen in its meticulous rally, with the stock now being up 578.51% over the past month.- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception …

Femasys : Corporate Presentation June 2023. Disrupting Convention in Women's Health Through Continuous Innovation. This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not …

Publish : 04 Oct 2023, 07:17 PM Update : 04 Oct 2023, 07:17 PM. Femasys (NASDAQ: FEMY) stock is down 50% over night from highs. A reasonable bet would be that FEMY stock will continue to fall back to more reasonable levels. For, as far as we can see at least, this is a flurry of speculation producing far too much movement for the objective ...

Find the latest Femasys Inc. (FEMY) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in permanent birth control and front-end infertility. Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Dec 31, 2022 · Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors Chuck Padala LifeSci Advisors, LLC +1-917-741-7792 [email protected]. Femasys Inc. Investor Contact: [email protected]. Media Contact ... In addition, Femasys has granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts ...ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. FEMY, a biomedical company focused on meeting significant unmet needs for women worldwide with a broad …WebAug 10, 2023 · Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update. August 10, 2023 08:00 ET ... Common stock, $.001 par, 200,000,000 authorized, ...

Employees: 30. 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE, GA 30024. 770-500-3910. femasys.com. Femasys Inc. focuses on women's healthcare market in the United States. The company develops permanent birth …Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA. Stock split history for Femasys since 2021.On average, Wall Street analysts predict. that Femasys's share price could reach $9.00 by Nov 14, 2024. The average Femasys stock price prediction forecasts a potential upside of 821.19% from the current FEMY share price of $0.98. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Femasys Inc. (NASDAQ: FEMY) shares fell lower on Wednesday, a pullback from Tuesday's surge in price following the announcement that the company received FDA 510(k) clearance for FemaSeed, CI. Earnings Flash (FEMY) FEMASYS Reports Q3 Revenue $86,186. Nov. 14. MT. Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc. Nov. 13. CI. Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation. Oct. 26.

Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...Grading Femasys Inc Stock. Before you choose to buy, sell or hold Femasys Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement.

Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M SA News Thu, Aug. 10 Femsys stock jumps 21% after FDA green lights FemBloc testingFEMY Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for Femasys in the last 3 months. The average price target is $10.67 with a high forecast of $13.00 and a low forecast of $7.00. The average price target represents a 620.95% change from the last price of $1.48.Get the latest Femasys Inc. (FEMY) stock news and headlines to help you in your trading and investing decisions.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide …WebFemasys Inc. is a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally ...Jul 27, 2023 · InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Shares of biomedical firm Femasys (NASDAQ:FEMY) more than doubled on Thursday.This followed an important intellectual property (IP ...

Get the latest Femasys Inc (FEMY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Find real-time FEMY - Femasys Inc stock quotes, company profile, news and forecasts from CNN Business.

Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.Femasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock …WebHistorical Stock Quote. Investment Calculator. Amount ($) Start Date: End Date: Compare to: S&P 500. Nasdaq 100. Dow 30. Other. Reinvest Dividends. Calculate Investment. ... At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party.On average, Wall Street analysts predict. that Femasys's share price could reach $9.00 by Nov 14, 2024. The average Femasys stock price prediction forecasts a potential upside of 821.19% from the current FEMY share price of $0.98.Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide by developing two lead revolutionary product candidates in late-stage clinical development for ...Operating Status Active. Last Funding Type Post-IPO Debt. Legal Name Femasys Inc. Stock Symbol NASDAQ:FEMY. Company Type For Profit. Contact Email [email protected]. Phone Number 1 (770) 500-3910. Femasys is a biomedical company focused on transforming women’s healthcare worldwide by …- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception …Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.Nov 24, 2023 · Femasys Inc (NASDAQ: FEMY) has seen a rise in its stock price by 1.31 in relation to its previous close of 0.90. However, the company has experienced a -9.52% decline in its stock price over the last five trading sessions. MarketBeat reported 2023-10-05 that Penny stocks can be a treasure trove of investment opportunities, and […] Jul 27, 2023 · FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ ... ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ...

Femasys Inc. FEMYNASDAQ FEMYNASDAQ 0.9138USD +0.0118 +1.31% At close at 16:59 UTC-8 See on Supercharts Overview News Ideas Financials Technicals Forecast …WebGainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.Read Full Company Summary for FEMY here. View Femasys Inc FEMY investment & stock information. Get the latest Femasys Inc FEMY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Instagram:https://instagram. lemonade term lifeworkhorse stock newsoptions classflowalgo reviews Femasys story: Femasys Inc Shares Close the Day 14.4 percent Lower - Daily Wrap - Nasdaq and other headlines for Femasys Stock spy prediction tomorrownasdaq emini Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in …Femasys expects the resulting patent, when issued, will have an anticipated expiration in 2039, at the earliest. In October, Femasys regained compliance with Nasdaq’s minimum bid price requirement, after having received a notice on June 1, 2023 from Nasdaq that they were not in compliance with such requirement. overnight hospital stay cost with insurance Operating Status Active. Last Funding Type Post-IPO Debt. Legal Name Femasys Inc. Stock Symbol NASDAQ:FEMY. Company Type For Profit. Contact Email [email protected]. Phone Number 1 (770) 500-3910. Femasys is a biomedical company focused on transforming women’s healthcare worldwide by …26 sept 2023 ... Femasys investors are celebrating on Tuesday after the company got approval from for its infertility treatment. This has FEMY stock rising.